WO2009000168A1 - Composé cyclohexènone d'antrodia camphorata utilisé pour réduire la fatigue physiologique - Google Patents

Composé cyclohexènone d'antrodia camphorata utilisé pour réduire la fatigue physiologique Download PDF

Info

Publication number
WO2009000168A1
WO2009000168A1 PCT/CN2008/070395 CN2008070395W WO2009000168A1 WO 2009000168 A1 WO2009000168 A1 WO 2009000168A1 CN 2008070395 W CN2008070395 W CN 2008070395W WO 2009000168 A1 WO2009000168 A1 WO 2009000168A1
Authority
WO
WIPO (PCT)
Prior art keywords
exercise
compound
cyclohexenone compound
fatigue
blood
Prior art date
Application number
PCT/CN2008/070395
Other languages
English (en)
Chinese (zh)
Inventor
Sheng-Yun Liu
Wu-Che Wen
Mao-Tien Kuo
Original Assignee
Golden Biotechnology Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Golden Biotechnology Corporation filed Critical Golden Biotechnology Corporation
Publication of WO2009000168A1 publication Critical patent/WO2009000168A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/22—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/753—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups

Definitions

  • the present invention relates to a compound for use in anti-fatigue, and more particularly to an anthraquinone
  • Antrodia camphorata also known as Antrodia camphorata, burdock or red locust, etc.
  • Antrodia camphorata is a perennial fungus belonging to the family Polyporaceae of Aphyllophorales. It is a endemic fungus of Taiwan and only grows in The inner wall of the hollow decayed heartwood of Taiwan's conservation tree species, Cinnamoum kanehirai Hay. Due to the extremely rare distribution of burdock trees, and the artificial piracy, the number of wild burdocks that can grow in it is even rarer. Because the fruiting bodies grow quite slowly, the growth period is only between June and October, so the price is very expensive.
  • Antrodia camphorata The fruit body of Antrodia camphorata is perennial, sessile, with cork to wood. It has a strong aroma of eucalyptus, and its morphology varies, with plate, bell, horseshoe or tower. It is flat and bright red at the beginning of life, and then it radiates and rewinds around it, and grows to the surrounding area. The color also changes to reddish brown or yellowish brown, and has many fine pores. It is also a medicinal herb of Antrodia camphorata. The most valuable part.
  • Niobium has the functions of detoxification, alleviating diarrhea, anti-inflammatory, treating liver-related diseases and anti-cancer.
  • Antrodia camphorata has many complex ingredients, such as triterpenoids, polysaccharides (such as ⁇ -D-glucan), and glands.
  • Adenosine vitamins (such as vitamin B, nicotinic acid), proteins (including immunoglobulins), superoxide dismutase (SOD), trace elements (eg calcium, phosphorus, wrong), nucleic acids, solid Alcohols and blood pressure stabilizing substances (such as antodia acid), these physiologically active ingredients are considered to have anti-tumor, immunity, anti-allergy, anti-bacteria, anti-hypertensive, hypoglycemic, cholesterol-lowering, liver protection and anti-fatiguekind of effect.
  • Triterpenoids are a general term for the combination of thirty carbon elements into hexagonal or pentagonal natural compounds.
  • the bitterness of Antrodia camphorata is mainly derived from triterpenoids.
  • Cherng et al. discovered the extract of Antrodia camphorata fruit body. Contains three new triterpenoids based on ergostane: antcin A, antcin B and antcin C (Chemg, IH, and Chiang, HC 1995. Three new triterpenoids from Antrodia cinnamomea. J. Nat. Prod. 58:365-371). Chen et al.
  • the present invention separates and purifies a compound of the formula (1) from the extract of Burdock;
  • X oxygen (0) or sulfur (S)
  • Y oxygen or sulfur
  • Y is oxygen or sulfur
  • R 2 is hydrogen, sulfhydryl or (CH 2 )m-CH 3
  • the cyclohexenone compound of the formula (1) and the formula (2) in the present invention is isolated and purified from an aqueous extract or an organic solvent extract of Antrodia camphorata, and the organic solvent may include an alcohol (for example, decyl alcohol, ethanol or propanol), an ester. (e.g., ethyl acetate), an alkane (e.g., hexane) or an alkylene (e.g., chlorodecane, ethyl chloride), but not limited thereto, preferably an alcohol, more preferably ethanol.
  • an alcohol for example, decyl alcohol, ethanol or propanol
  • an ester. e.g., ethyl acetate
  • an alkane e.g., hexane
  • an alkylene e.g., chlorodecane, ethyl chloride
  • the present invention applies the compound to the reduction In the physiological fatigue, immediately after the high-intensity exhaustion exercise of 80% maximal oxygen uptake (80% V0 2 max), the immediate addition of the anthraquinone cyclohexenone compound contributes to the in vivo creatine phosphate kinase (CPK) and blood.
  • CPK creatine phosphate kinase
  • the metabolism of ammonia (Ammonia) and the recovery of its concentration slow down muscle cell damage caused by exercise, and improve the central fatigue and peripheral fatigue caused by blood ammonia accumulation in the blood, thereby achieving anti-fatigue effect.
  • 1 is a result of in vivo creatine kinase concentration at each time point after supplementation with a placebo or anthraquinone cyclohexenone compound in a subject with or without exercise in the embodiment of the present invention
  • Placebo PR
  • er exercise and placebo
  • PE placebo
  • ⁇ no exercise and administration of anthraquinone cyclohexenone compound
  • A exercise and administration of anthraquinone cyclohexenone compound (DE);
  • Antrodia camphorata mycelium, fruiting body or a mixture of the two is taken, and extracted by water or an organic solvent by a known extraction method to obtain an aqueous extract of Antrodia camphorata or an organic solvent extract.
  • the organic solvent may include an alcohol (such as decyl alcohol, ethanol or propanol), an ester (such as ethyl acetate), an alkane (such as hexane) or an alkyl halide (such as chlorodecane, ethyl chloride), but Not limited to this.
  • alcohols such as decyl alcohol, ethanol or propanol
  • an ester such as ethyl acetate
  • an alkane such as hexane
  • an alkyl halide such as chlorodecane, ethyl chloride
  • the extracted aqueous extract of Antrodia camphorata or the organic solvent extract can be further separated and purified by high performance liquid chromatography, and then each fraction is subjected to a fatigue-resistant biochemical test. Finally, component analysis is performed on the liquid separation with anti-fatigue effect, and the components that may have anti-fatigue effects are further subjected to biochemical tests related to fatigue resistance. Finally, it was found that the compound of the formula (1) / formula (2) of the present invention has an effect of alleviating physiological fatigue.
  • the collected Antrodia camphorata extract was analyzed by high performance liquid chromatography using a column of RP18, and decyl alcohol (A) and 0.1%-0.5% aqueous acetic acid solution (B).
  • A decyl alcohol
  • B ratio 0.1%-0.5% aqueous acetic acid solution
  • B ratio 0.1%-0.5%
  • the mobile phase the ratio of the solution is: 0 ⁇ 10 minutes, B ratio is 95% ⁇ 20%; 10 ⁇ 20 minutes, B ratio is 20% ⁇ 10%; 20-35 minutes, B ratio is 10 % ⁇ 10%; 35-40 minutes, B ratio is 10% ⁇ 95%), eluted at a rate of 1 ml per minute, and analyzed by UV-visible full wavelength detector.
  • the eluate from 25 minutes to 30 minutes is collected and concentrated to obtain a pale yellow powdery solid product, which is 4-hydroxy-2,3-dimethoxy-6-mercapto-5 (3,7,11) - Tridecyl-2,6,10-dodecatriene)-2-cyclohexenone.
  • the molecular formula is C 24 H 38 0 4
  • the molecular weight is 390
  • the melting point (mp ) is 48 ° C - 52 ° C.
  • the nuclear magnetic resonance (NMR) analysis values are as follows: lH-NMR (CDC13) 5 (ppm): 1.51, 1.67, 1.71, 1.75, 1.94, 2.03, 2.07, 2.22, 2.25, 3.68, 4.05, 5.07 and 5.14.
  • this experiment uses 80% maximal oxygen uptake exercise load for subsequent depletion exercise, so the maximum oxygen uptake should be measured first to further Estimate the speed of 80% of the maximum oxygen uptake.
  • oxygen uptake refers to the product of cardiac output and arteriovenous blood oxygen concentration difference
  • the maximum oxygen uptake refers to a person at sea level, when engaged in the most intense exercise, tissue cells can be consumed or utilized every minute. The highest value of oxygen, which is the best index for evaluating cardiorespiratory endurance.
  • the present invention uses a direct measurement method in the laboratory, using an in-situ treadmill to directly increase the exercise load to the maximum exercise load, and directly measures with a gas analyzer.
  • the maximum oxygen uptake this progressive incremental exercise load sustained exercise, can induce the actual maximum oxygen uptake capacity, so it is a method to directly and accurately measure the maximum oxygen uptake.
  • Basic data collection of subjects The invention adopts 15 males who are 20 years old and healthy and voluntary, and selects those who have not taken drugs, have normal liver and kidney function, no cardiovascular disease, and have no smoking, drinking, and using nutritional supplements on weekdays, and measure the records.
  • Basic data for each subject included: age, height, weight, and BMI.
  • Subjects need to have an empty stomach for at least eight hours before the formal test, and maintain a normal diet during the test period and avoid taking nutritional supplements or other medications to avoid affecting the experimental data.
  • Subjects must undergo a second pre-test before formal testing to determine the maximum oxygen uptake (V0 2 max ) and estimate the exercise load of 80% of the maximum oxygen uptake, followed by an 80% maximal oxygen uptake. The test is confirmed to ensure the exercise intensity of the subject's 80% maximal oxygen uptake at this particular load, and the test procedure is detailed below.
  • the maximum oxygen uptake test is performed. Before the subject arrives, the oxygen analyzer of the gas analyzer (Vmax Spectra, SensorMedics) and the standard gas calibration of different concentrations are required. After the subject arrives, put on the heartbeat test table (Polar810i) and record the resting heart rate, place the heartbeat test strip close to the subject's heart, and place the test table within 1 meter of the test strip.
  • Vmax Spectra, SensorMedics the oxygen analyzer of the gas analyzer
  • standard gas calibration of different concentrations are required.
  • the subject arrives put on the heartbeat test table (Polar810i) and record the resting heart rate, place the heartbeat test strip close to the subject's heart, and place the test table within 1 meter of the test strip.
  • the mask is connected to the breathing tube, and the breathing tube is connected to the gas analyzer, so that the gas exhaled by the subject can be transmitted to the gas analyzer through the gas mask and the breathing tube.
  • the running speed of the treadmill is fixed at 9.6 km/hr, and the treadmill is set to 0% slope within 0 ⁇ 3 minutes from the start of the test. After starting the test for 3 minutes, the treadmill should be increased by 3% every 3 minutes until Subjects stop exercising and stop exercising.
  • the oxygen uptake 1 minute before each slope and before the exercise failure was obtained, and the maximum oxygen uptake obtained in the test was the maximum oxygen uptake.
  • the maximum oxygen uptake criteria must meet at least two of the following conditions to determine the maximum oxygen uptake: (a) The subject has tried his best to not continue the exercise test (the subject's footsteps are slow) (b) The heart rate is (220 - age) ⁇ 10 beats / min; (c) The respiratory quotient (RQ) must be greater than 1 ⁇ 1 or more; (d) Self-conscious scale ( Rating perceived exertion, RPE) has reached the stage of 18 or 19.
  • the 80% maximal oxygen uptake rate can be further obtained by the regression equation of the maximum oxygen uptake and load intensity obtained from the pre-test.
  • This calculation process uses the oxygen consumption and the speed obtained in the maximal oxygen uptake test.
  • the extensive definition of muscle fatigue during exercise is that the individual's physiological processes cannot maintain their functions at a certain level, or the organs cannot maintain the predetermined exercise intensity.
  • the causes of physical activity fatigue may include psychological, physiological and biochemical aspects, among which, biochemical fatigue
  • the underlying mechanisms include both central and peripheral fatigue.
  • the mechanisms that cause central fatigue include hypoglycemia, changes in the concentration of key amino acids in the blood, and changes in the concentration of neurotransmitters in the brain.
  • the mechanism of peripheral fatigue is phosphoric acid in the muscle.
  • Exhaustion of phospocreatine (PC) leads to energy shortages such as increased blood ammonia, hepatic glucose depletion in muscles, and insufficient oxygen supply, as well as increased lactic acid due to accumulation of hydrogen ions in muscles and accumulation of phosphate in muscles. Stacking factors.
  • the present invention provides a subject with a placebo containing an anatase ring cyclohexenone compound and an anthrax-free cyclohexenone compound, and subjecting the subject to a depletion exercise having an intensity of 80% of the maximum oxygen uptake exercise load.
  • a depletion exercise having an intensity of 80% of the maximum oxygen uptake exercise load.
  • the content of fatigue indexes such as acid kinase, blood lactic acid, blood sugar, blood ammonia and free fatty acid in the subject was analyzed, and the anti-fatigue of the anthraquinone cyclohexenone compound was measured after the exhaustion exercise. efficacy.
  • each subject is required to undergo the following tests: no exercise and placebo (PR), exercise and placebo (PE), no exercise and given burdock
  • PR no exercise and placebo
  • PE exercise and placebo
  • burdock The cyclohexenone compound (DR) and the subject who is exercised and given the anthraquinone cyclohexenone compound (DE), and who are tested in different groups, need to rest after a week after completing the one-week trial of the group.
  • the next set of tests is continued until each subject completes the above four sets of tests.
  • the exercise is performed on the treadmill with the intensity of the 80% maximal oxygen uptake exercise load (7.61 ⁇ 1.87) measured above, and runs until the subject is exhausted, and is given after exercise.
  • the subject was anthraquinone cyclohexenone compound or placebo; in addition, the placebo was administered in an amount of 0.2 g/kg (kg) per day, and the anthraquinone cyclohexenone compound was administered in an amount of 0.2 g/kg (kg) per day.
  • the test was conducted for seven days, and venous blood was collected at 0, 0.5, 1, 2, 24, 48, 72, 120, and 168 hours before exercise and after exhaustive exercise. Blood was collected with anticoagulant (eg, EDTA).
  • anticoagulant eg, EDTA
  • Serum creatine kinase is produced in human skeletal muscle, myocardium, brain and prostate, among which skeletal muscle is the most abundant, accounting for 96% of the total body; under normal circumstances, serum creatine kinase activity is very low.
  • creatine kinase can catalyze the high energy riding acid bond between adenosine triphosphate (ATP) and phosphate creatine (PC).
  • ATP adenosine triphosphate
  • PC phosphate creatine
  • ADP + PC ⁇ ATP + Creatine To ensure rapid muscle movement, the energy required for muscle contraction and the re-synthesis of ATP are promoted.
  • the reason why the increase of creatine kinase activity during exercise is caused by hypoxia during exercise, accumulation of metabolites, constant imbalance of intracellular and extracellular calcium ions, increase of permeability of myocyte membrane, or damage of myocyte membrane, for example. Muscle pulls mechanical damage or produces a hematoma, which in turn causes creatine kinase to release into the blood circulation, so creatine kinase is often used as an indicator of exercise intensity and muscle cell damage.
  • the method for measuring the concentration of creatine kinase in blood is measured by a dry automatic blood analyzer (Johnson & Johnson DT-60 II) and by the principle of enzyme action and colorimetric assay. After adding the creatine phosphate glucose oxidase reaction to the quantified plasma, 4-aminoantipyrine and 1,7-dihydroxynaphthalene were added. After the action of peroxidase, a white compound was produced, and the absorbance was measured at a wavelength of 680 nm, and then the concentration of creatine kinase was converted. The results are shown in Table 2 and Figure 1. Table 2. Creatine kinase concentration (U/L) at various time points after exercise or no exercise and supplementation with placebo or burdock cyclohexenone compound, exercise and post-exercise exercise after exercise After exercise, after exercise, after exercise, after exercise, after exercise, after exercise
  • * indicates p ⁇ .05: there is a difference from the pre-test ratio; a indicates p ⁇ .05: PR group significantly larger than the simultaneous point
  • d indicates p ⁇ .05: DE group significantly larger than the contemporaneous point.
  • the group with exercise and placebo (PE) was At 0, 0.5, 1, 2, and 24 hours after exercise, the concentration of creatine kinase continued to increase and was significantly (p ⁇ 0.05) higher than the concentration of creatine kinase before exercise, which also indicates exercise intensity of the subject.
  • phosphorylase can be activated to increase the rate of hepatic glycolytic decomposition in the muscle, and the increased adrenaline accelerates the liver glycolytic reaction. (glycogenolysis), which in turn increases blood glucose levels.
  • the fatigue caused by high-intensity exhaustion exercise with 80% maximal oxygen uptake is often caused by the continuous use of blood sugar in the oxidative metabolism process, resulting in hypoglycemia, which leads to the depletion of glycogen in the muscle. Therefore, detection The utilization of sugar in the body during exercise can be used as one of the indicators for observing physiological fatigue.
  • the method for measuring blood glucose concentration according to the present invention is measured by a dry automatic blood analyzer (Johnson & Johnson DT-60 II) and by the principle of enzyme action and colorimetric measurement. After adding glucose oxidase to the quantitative plasma, 4-aminoantipyrine and 1,7-dihydroxynaphthalene are added to the plasma. 4 substance enzyme Consolation
  • peroxidase produces a red compound with the following reaction formula: glucose oxidase
  • * indicates p ⁇ .05: there is a difference from the pre-test ratio; a indicates p ⁇ .05: PR group significantly larger than the simultaneous point
  • Blood ammonia is a metabolite of protein, which is mainly caused by the decomposition of amino acids in the purine nucleotide cycle (PNC) and the deamination of adenosine monophosphate (AMP).
  • PNC purine nucleotide cycle
  • AMP adenosine monophosphate
  • Depletion of creatine phosphate causes adeninenucleotide in the tissue to decompose to accelerate the re-synthesis of ATP, which produces a large amount of blood ammonia, and an increase in blood ammonia concentration changes the center.
  • the role of the nervous system changes the extracellular pH, electrolyte concentration, and neurotransmitter concentration, and interferes with the Krebs cycle, causing fatigue. Therefore, blood ammonia accumulation is also causing central fatigue and peripheral fatigue.
  • blood ammonia is often used as one of the indicators of fatigue.
  • the method for measuring blood ammonia concentration uses a dry automatic blood analyzer (Johnson & Johnson DT-60 II) and adds a coloring agent bromophenol blue (bromphenol) to the quantitative plasma by the principle of colorimetric measurement. Blue), after the action, produces a blue compound with the following reaction formula:
  • Ketolation has exercise 45.86 118.07 57.64 44.86 37.53 27.93 20.93 30.07 23.21 24.86 compound
  • * indicates p ⁇ .05: there is a difference from the pre-test ratio; a indicates p ⁇ .05: PR group significantly larger than the simultaneous point
  • the blood ammonia concentration shown by exercise and given to the Antrodia camphora cyclohexanone compound (DE) group was significantly (p ⁇ 0.05) lower than that at 24 hours after exercise.
  • the blood concentration of the same exercise group and the placebo (PE) group was similar to the value before the exercise, and there was no significant decrease in the blood ammonia concentration. Therefore, the above results show that supplementing the anthraquinone cyclohexenone compound after exercise contributes to the metabolism of blood ammonia, so that the blood ammonia accumulated in the body after exercise can be rapidly metabolized and thus slowed down.
  • Lactic acid is a product of the metabolism of glycogen and glucose in muscle and liver through anaerobic glycolysis. In a quiet state, the amount of lactic acid produced is small. When it is intense or prolonged, the tissue hypoxia is more obvious. The rate of oxygen metabolism is increased, and when the rate of lactic acid production is higher than the rate of oxidative metabolism of lactic acid by mitochondria, increased lactic acid is gradually accumulated in the muscle. The accumulation of lactic acid causes the concentration of hydrogen ions in the muscle to rise and the pH to decrease, which in turn inhibits the activity of the phospholyzed phosphofructokinase (PFK), resulting in a decrease in the rate of glycolytic reaction and a decrease in the rate of ATP re-synthesis.
  • PFK phospholyzed phosphofructokinase
  • the method for measuring blood lactic acid concentration uses a dry automatic blood analyzer (Johnson & Johnson DT-60 II), and adds lactate oxygenase to the quantitative plasma by the principle of enzyme action and colorimetric determination. After (lactate oxidase) reaction, 4-aminoantipyrine and 1,7-dihydroxynaphthalene are added to the solution, which is red by the action of peroxidase. a compound having the following reaction formula: lactate oxidase
  • * indicates p ⁇ .05: there is a difference from the pre-test ratio; a indicates p ⁇ .05: PR group significantly larger than the simultaneous point
  • the blood lactate concentration value was significantly (p ⁇ 0.05) higher than that without exercise and given placebo (PR) and without exercise and given to the group of the cow's anthraquinone cyclohexenone compound (DR), and the group with exercise
  • PR placebo
  • DR cow's anthraquinone cyclohexenone compound
  • the production of free fatty acids is derived from the hydrolysis of adipose tissue between fibers, or intracellular triglycerides.
  • the glycogen stored in the muscle will be depleted, and as the duration of exercise increases, the rate of glycolytic will gradually decrease, and the utilization of energy in the body tends to utilize fatty acids.
  • the production of ATP is reduced, thus causing fatigue;
  • the rate of fat decomposition is increased, and the concentration of free fatty acids in plasma is increased, free fatty acids compete with tryptophan in blood for albumin (Albumin).
  • albumin albumin
  • the binding position causes an increase in free tryptophan in the blood. Tryptophan is a precursor of serotonin.
  • the rate of serotonin synthesis increases.
  • the serotonin in the brain increases, it will damage some aspects of the central nervous system. For example, reducing the activity of dopamine can also lead to fatigue and sleep reaction. Therefore, the concentration of free fatty acids in the blood can be used as a lipolysis. And indicators of fatigue.
  • the method for measuring the concentration of free fatty acids of the present invention using the principle of enzyme action and colorimetric determination, adding acyl-CoA synthetase to acyl-CoA synthetase, acyl-CoA synthase (acyl) CoA oxidase), after the action of peroxidase, produces a purple compound with the following reaction formula:
  • the compound has motion 0.34 0.91 0.60 0.61 0.59 0.41 0.28 0.44 0.30 0.32 (DE) ⁇ 0.03 ⁇ 0.14* ac ⁇ 0.08* ac ⁇ 0.09* ae ⁇ 0.08* ae ⁇ 0.06 c ⁇ 0.04 ⁇ 0.05 c ⁇ 0.04 ⁇ 0.06
  • * indicates p ⁇ .05: there is a difference from the pre-test ratio; a indicates p ⁇ .05: PR group significantly larger than the simultaneous point
  • d indicates p ⁇ .05: the DE group significantly larger than the contemporaneous point is shown in Table 6 and Figure 5, with exercise and placebo (PE) and exercise and given to the group of O. chinensis cyclohexenone compounds (DE), Within 2 hours after high-intensity exhaustion exercise with 80% maximal oxygen uptake, the concentration of free fatty acids in the blood was significantly (p ⁇ 0.05) higher than no exercise and placebo (PR) and no exercise and given to Antrodia camphorata Group of ketene compounds (DR). There was no significant difference in blood free fatty acid concentration values between exercise and placebo (PE) and exercise and administration of Antrodia camphora (DE) at various time points after exercise. > 0.05), this result shows that supplementation with anthocyanin cyclohexenone after exercise has no effect on the metabolism of free fatty acids in the blood.
  • the results of the invention show that the anthocyanin compound is supplemented immediately after the high-intensity exhaustion exercise with 80% maximal oxygen uptake, and the concentration of creatine kinase rises only immediately after exercise, and the muscle is 0.5 hours later.
  • the acid kinase concentration returned to pre-exercise levels, and this result showed that the addition of Antrodia camphorata immediately after exhaustive exercise had a significant (P ⁇ 0.05) effect on the metabolism of creatine kinase; whereas after exercise, the metabolism of blood ammonia, immediately after exhaustive exercise
  • the group supplemented with anthocyanin compound (DE) was added 2 hours after exercise.
  • the recovery effect was significantly better (p ⁇ 0.05) than the group without supplemented with anthocyanin compound (PE); in addition, fatigue indicators such as blood sugar, blood lactate and free fatty acids were in exercise and given placebo (PE)
  • anthraquinone cyclohexenone compound (DE) There was no significant difference between the two groups with exercise and given the anthraquinone cyclohexenone compound (DE). Therefore, supplementation with anthocyanin cyclohexenone after the high-intensity exhaustion exercise of 80% of the maximum oxygen uptake contributes to the recovery of creatine kinase and blood ammonia in the body, thereby achieving the effect of slowing down physiological fatigue.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des composés cyclohexènone d'Antrodia camphorata utilisés pour réduire la fatigue physiologique, en particulier la 4-hydroxy-2,3-diméthoxy-6-méthy-5[3,7,11-triméthy-dodéca-2,6,10-triényl]-cyclohex-2-ènone isolée à partir d'un extrait d'Antrodia camphorata, qui sont capables de réduire efficacement la fatigue physiologique. Dans la présente invention, l'administration desdits composés immédiatement après des exercices physiques très intenses à plat ventre avec 80 % d'absorption maximale d'oxygène peut augmenter le métabolisme de la créatine kinase et de l'ammoniac sanguin et peut favoriser la récupération de leurs concentrations, en ayant ainsi pour effet de réduire la fatigue physiologique.
PCT/CN2008/070395 2007-06-27 2008-03-03 Composé cyclohexènone d'antrodia camphorata utilisé pour réduire la fatigue physiologique WO2009000168A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN200710126805.0 2007-06-27
CN2007101268050A CN101333156B (zh) 2007-06-27 2007-06-27 牛樟芝环己烯酮化合物的制备方法及其应用

Publications (1)

Publication Number Publication Date
WO2009000168A1 true WO2009000168A1 (fr) 2008-12-31

Family

ID=40185185

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2008/070395 WO2009000168A1 (fr) 2007-06-27 2008-03-03 Composé cyclohexènone d'antrodia camphorata utilisé pour réduire la fatigue physiologique

Country Status (2)

Country Link
CN (1) CN101333156B (fr)
WO (1) WO2009000168A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110146499B (zh) * 2019-06-21 2022-03-22 长春汇力生物技术有限公司 一种定量检测过氧化氢浓度的干片检测试剂卡及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1666982A (zh) * 2004-03-10 2005-09-14 善笙生物科技股份有限公司 来自牛樟芝菌丝体的新混合物和化合物及其用途
US7342137B1 (en) * 2007-01-08 2008-03-11 Golden Biotechnology Corporation Cyclohexenone compounds from Antrodia camphorata and application thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1666982A (zh) * 2004-03-10 2005-09-14 善笙生物科技股份有限公司 来自牛樟芝菌丝体的新混合物和化合物及其用途
US7342137B1 (en) * 2007-01-08 2008-03-11 Golden Biotechnology Corporation Cyclohexenone compounds from Antrodia camphorata and application thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHEN C.-H. ET AL.: "New Steroid Acids from Antrodia Cinnamomea a Fungal Parasite of Cinnamomum micranthum", JOURNAL OF NATURAL PRODUCTS, vol. 58, no. 11, 1995, pages 1655 - 1661, XP008138392, DOI: doi:10.1021/np50125a002 *
CHENG I.-H. ET AL.: "Triterpenoids from Antrodia cinnamomea", PHYTOCHEMISTRY, vol. 41, no. 1, 1996, pages 263 - 267 *
CHERNG I.-H. ET AL.: "Three new triterpenoids from Antrodia cinnamomea", JOURNAL OF NATURAL PRODUCTS, vol. 58, no. 3, 1995, pages 365 - 371, XP008138391 *
CHIANG H.-C. ET AL.: "A sesquiterpene lactone, phenyl compounds from Antrodia cinnamomea", PHYTOCHEMISTRY, vol. 39, no. 3, 1995, pages 613 - 616, XP008138393, DOI: doi:10.1016/0031-9422(95)00025-3 *
YANG S.-W. ET AL.: "Steroids and triterpenoids of Antrodia cinnamomea-a fungus parasitic on Cinnamomum microanthus", PHYTOCHEMISTRY, vol. 41, no. 5, 1996, pages 1389 - 1392, XP008138394 *

Also Published As

Publication number Publication date
CN101333156B (zh) 2011-07-20
CN101333156A (zh) 2008-12-31

Similar Documents

Publication Publication Date Title
Bailey et al. Regulation of free radical outflow from an isolated muscle bed in exercising humans
Ravussin et al. Effect of elevated FFA on carbohydrate and lipid oxidation during prolonged exercise in humans
Porter et al. The effect of oral coenzyme Q10 on the exercise tolerance of middle-aged, untrained men
Pincemail et al. Exercise induces pentane production and neutrophil activation in humans. Effect of propranolol
TWI394574B (zh) Application of Cynanchum auranthone Cyclohexenone Compounds in the Preparation of Drugs for Mitigating Physiological Fatigue
CN111557910B (zh) 一种靶向肝脏的nmn脂质体纳米粒子及其制备方法和应用
TWI394572B (zh) Application of Cynanchum aurantii Cyclohexenone Compounds in the Preparation of Drugs for the Treatment of Autoimmune Diseases
CA2757673A1 (fr) Complements alimentaires contenant des alpha-ceto-acides, pour etayer le traitement du diabete
Khajali et al. Methylglyoxal and pulmonary hypertension in broiler chickens
CN111803503A (zh) 吡咯喹啉醌在制备抗疲劳及缓解氧化应激损伤的产品中的应用
CN108514114A (zh) 基于线粒体营养素理论的缓解体力疲劳的组合物及用途
WO2009000168A1 (fr) Composé cyclohexènone d'antrodia camphorata utilisé pour réduire la fatigue physiologique
CN1833665A (zh) 山竹果皮提取物及其提取方法及其药物用途
Lehnert et al. Excretion of 2-methyl-3-oxovaleric acid in propionic acidemia
JP5106935B2 (ja) 生理的疲労の緩和に用いるベニクスノキタケのシクロヘキサンケトン化合物
RU2455702C1 (ru) Способ диагностики и коррекции эндотелиальной дисфункции при сосудистых осложнениях аллоксанового диабета в эксперименте
TWI605820B (zh) 用以改善酒精中毒之中草藥複方組合物及其用途
JP2009019020A (ja) 自己免疫疾病治療に用いるベニクスノキタケシクロヘキサンケトン化合物
US10092590B2 (en) Composition of HMB and ATP and methods of use
Lyon et al. Inhibition of Na (+)-K (+)-ATPase by digoxin and its relation with energy expenditure and nutrient oxidation rate
Hadj et al. The clinical application of metabolic therapy for cardiovascular disease
CN111387502A (zh) 一种具有辅助降血糖作用的蜂胶苦瓜组合物及其制备方法
CN105831767A (zh) 用于增强免疫力和抗疲劳的组合物及其制备方法和应用
CN109157548A (zh) 一种具有抗疲劳和壮阳功能的组合物及制备方法
US20190192453A1 (en) Methods for improving physical performance and capsicum compositions used therein

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08715131

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08715131

Country of ref document: EP

Kind code of ref document: A1